is the Director of Medical Affairs at Haystack Oncology, a Quest Diagnostics company. In her role, Dr. Sloane provides key clinical strategy support and primary oversight for the clinical development of Haystack’s cutting edge circulating tumor ctDNA minimal residual disease technology. She engages closely with the medical community to establish and execute clinical development initiatives that specifically address current and future needs to improve patient care. Hillary has an extensive background in molecular diagnostics and liquid biopsy, with experience in clinical development and medical scientific affairs roles in the oncology diagnostics industry. She holds a PhD in bioanalytical chemistry from The University of Virginia.